A life science venture capital firm with strong China expertise and global capabilities founded in 2017, discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. The firm operates offices in USA and China.
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.
The firm has no specific requirement for the company & management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC With Strong China Expertise Invests in Novel Therapeutics Across All Modalities, from Early to Growth Stage
20 May- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Listen to the Podcast
Top Posts
- LSN Partners with Shinhan Square Bridge (S2 Bridge), a Global Startup Acceleration Platform
- Eli Lilly Comes to RESI
- Hot Investor Mandate: PE Firm With Virtual Pharma Model Invests in Promising Early Stage Therapeutic Assets Across the Globe, Providing Up to $25M in Funding
- Hot Investor Mandate: VC Firm With US and Israel Offices Seeks Pre-Seed and Seed Stage Companies, Strong Interest in Therapeutics and Diagnostics
- Hot Investor Mandate: Family Office Manages Evergreen Fund, Investing Up to $10M in Medical Devices Companies in Cardiology, Orthopedics, and More With Strong USA Focus
- Partnering Opens Soon
- Hot Investor Mandate: USA-Based Fund With China-Based Global Innovation Center Invests Broadly in All Life Science Sectors, With Recent Interest in Disease-Modification Therapies
- Drug Development: What Does It Cost, and Who Has The Capital?
- First Loss Capital - What, Why & How?
- Hot Investor Mandate: USA-Based VC Firm Invests in Life Science Companies From Seed to Series B Rounds, With Strong Interest in AI-Based Technologies
Recent Posts
- Eli Lilly Comes to RESI
- LSN Partners with Shinhan Square Bridge (S2 Bridge), a Global Startup Acceleration Platform
- Partnering Opens Soon
- Hot Investor Mandate: PE Firm With Virtual Pharma Model Invests in Promising Early Stage Therapeutic Assets Across the Globe, Providing Up to $25M in Funding
- Hot Investor Mandate: VC Firm With US and Israel Offices Seeks Pre-Seed and Seed Stage Companies, Strong Interest in Therapeutics and Diagnostics
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
LSN Twitter
- Eli Lilly @LillyPad comes to RESI Boston Sept.21-23 adding value to the community with new opportunities for… twitter.com/i/web/status/1… 8 hours ago
- Join Andrew Meadow (Health Innovation Capital) at RESI Boston, September 21-22. The Oncology Innovation panel discu… twitter.com/i/web/status/1… 1 day ago
- Join Lisa Fabiny-Kiser (SENS Research Foundation) at RESI Boston, September 21-22. The New, Now, and Next in Longev… twitter.com/i/web/status/1… 2 days ago
- Congratulations to RESI Boston Innovator’s Pitch Challenge finalist, @AlgoDx! CEO, David Becedas will pitch to a pa… twitter.com/i/web/status/1… 2 days ago
- Join Antoinette Lowre and Joey Wong for a FREE bootcamp: Keys to Successful Partnering. #Earlystage #lifescience en… twitter.com/i/web/status/1… 3 days ago
- Join LSN & the Pre-Incubation Centre at The Chinese University of Hong Kong @CUHKofficial August 23- 24, 7-9 AM EDT… twitter.com/i/web/status/1… 4 days ago
Leave a Reply